Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1NET 1Genitourinary 1Endocrine 1

Conditions

Neoplasm Metastasis 2Neuroendocrine Tumors 1Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancer 1

Interventions

pembrolizumab 157Gemcitabine 140Capecitabine 123Paclitaxel 121Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Docetaxel 98Leucovorin 97Cisplatin 90Radiosurgery 88Irinotecan 88Carboplatin 86Cyclophosphamide 72Cetuximab 72Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × LY2584702 × Clear all
NCT01115803 2019-02-05

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
29 enrolled 19 charts
EndocrineGenitourinaryNETThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT01241461 2018-08-21

A Study of LY2584702 in Solid Tumors

Eli Lilly and Company

Phase 1 Completed
9 enrolled 9 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡